Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATENT-CHILD: Open-label dose-titration study of riociguat in children with PAH
jRCT2080223235Phase 3Completed
- Sponsor
- Bayer
- Start
- Jun 2016
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of riociguat in pulmonary arterial hypertension (PAH), Plexogenic Pulmonary Arteriopathy and Heritable Pulmonary Arterial Hypertension (HPAH), sponsored by Bayer. Primary endpoints: Safety and tolerability of riociguat and Pharmacokinetics of riociguat. Started Jun 2016; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)Plexogenic Pulmonary ArteriopathyHeritable Pulmonary Arterial Hypertension (HPAH)
Beyond the preview
Go deeper on jRCT2080223235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223235.